 |
Our Management |
|
A management team with strength in knowledge, success and more than 150 combined years of experience in biotechnology.
|
|
| |
| H. Raymond Cairncross: |
Top |
| Co-Founder and CEO |
|
Mr. Cairncross has over 25 years of experience as a founder, Chairman, CEO, director of and counsel to high-tech and other companies. Ray formed the Seattle law firm of Cairncross & Hempelmann, specializing in business planning, corporate finance, and commercial transactions. As the firm's only Managing Partner, he developed and maintained a full practice focused on business planning, strategy, major commercial transactions, and financings. His first role as a founder was for Horizon Airlines where he was General Counsel and business strategist, negotiating the acquisition of Air Oregon and Cascade Airlines, leading to the sale of Horizon to Alaska Airlines.
Utilizing his legal and business expertise, Ray founded several high-tech companies including Ostex International, Inc., where he served as Chairman and CEO. The Seattle biotechnology company was based upon an innovative technology transfer arrangement with the University of Washington. He successfully negotiated complex domestic and international licensing and partnership arrangements, and equity and non-dilutive financings, taking Ostex public in the mid 1990's. Ray co-founded Omeros Medical Systems, Inc., a company with a successful pharmaceutical platform technology that delivers analgesic, anti-inflammatory, anti-spasm and/or anti-restenosis agents directly to the surgical site during arthroscopic, urologic, cardiovascular and general surgical procedures. As with Ostex, Omeros has developed strong intellectual property position and patent portfolio, along with an effective regulatory strategy. Ray co-founded Onconome, Inc. (formerly Tessera, Inc.) in 2001, has been its C.E.O. since 2003.
|
Ray received his BA degree from Stanford University and his JD degree from the University of Washington.
|
|
 |
| Randall Brock: |
Top |
| President |
|
Mr. Brock has over twenty-five years experience in the medical device and pharmaceutical industry in several roles including accounting and finance, manufacturing, human resources, and general research and development administration. Randy joined Onconome in July 2006.
Before joining Onconome, Randy was Controller for Nastech Pharmaceutical Company, Inc. While at Nastech, Randy worked with the CEO in negotiating a multi-million product licensing agreement with Pharmacia for the company's intranasal apomorphine product for sexual dysfunction. Prior to Nastech, Randy was Vice President, R&D Finance and Operations for Nycomed Amersham, Inc. an international pharmaceutical company with market leading contrast agent products in X-Ray CT, MRI and Nuclear Radiology. Prior to Nycomed, Randy was Sr. Vice President, Finance and Operations and CFO for Salutar, Inc., a development stage company discovering and developing in-vivo contrast agents for MRI. Salutar was sold to Nycomed for an 8 fold return on venture funding. Previously to his years at Salutar, Randy held top manufacturing positions at International Diagnostic Technologies, Inc., and Smith Kline Instruments, Inc., both manufacturers of in-vitro diagnostic products for blood chemistries and infectious diseases.
|
Randy received his B.S. degree in Medical Microbiology from California State University, Chico and his MBA from the University of Santa Clara.
|
|
|
| Dan Clemens: |
Top |
| Managing Director, Technical Operations |
|
Mr. Clemens joined Onconome in September 2005 after working as a consultant to Onconome for the previous 9 months. He has worked in the in-vitro diagnostic and biotechnology business for over 20 years, most recently doing consulting for medical device product development. From 1990 through 2003, Dan directed all R&D activities for Ostex International, Inc., focused on developing diagnostic technologies for osteoporosis and osteoarthritis. The products developed under his direction, and marketed for clinical use, include the Osteomark® Urine NTx ELISA, Serum NTx ELISA, and NTx Point-of-Care Device. Prior to Ostex, he was an R&D scientist at Genetic Systems Corporation in Seattle, a biotechnology company that successfully developed and marketed one of the first HIV antibody blood tests, as well as blood virus tests for hepatitis B. He began his career as part of the team that developed the TDx automated immunoassay system at Abbott Laboratories in North Chicago, Illinois.
|
Dan holds a Master of Science Degree from Washington State University.
|
|
|
| Michael Hass: |
Top |
| Director, Technology Assessment |
|
Dr. Hass joined Onconome in July 2007 after serving as a consultant to the Company for 16 months. He has over 40 years of experience in protein chemistry, of which 25 years has been working in in vitro diagnostics. Mike was in the Cancer Diagnostics Business Unit at Abbott Laboratories, where he was responsible for the technical assessment of new diagnostic opportunities for six years. He spent the remaining seven years at Abbott leading multifunctional product development teams, which produced the Abbott IMx PSA immunoassay and eight other FDA-approved cancer diagnostic tests. Subsequently, he was vice president of R/D at Bard Diagnostics in Seattle. His team developed two bladder cancer tests, BTA Trak and BTA Stat, both of which are FDA-approved.
|
Mike holds a BA in chemistry from Northwestern University, a Ph.D. in biochemistry from Duke University, and post-doctoral training at the University of Washington.
|
|
|
| Io Dolka: |
Top |
| Manager, Business Development |
|
Ms. Dolka heads the in-licensing efforts at Onconome. She has been involved with the biotechnology sector for the last 7 years and her background combines both business and science experience. Io joined Onconome in July 2006.
Prior to joining Onconome, Io worked at Primal, Inc, a Seattle biotechnology company focusing on treatments for behavioral disorders. At Primal, she participated in the development of large scale, saturating mutagenesis of the mouse genome, a technology with major implications in deciphering the function of each and every gene. Io was also a guest researcher at the National Cancer Institute in Maryland, where she was involved in the discovery of novel markers for cell tagging and the generation of specialized retroviral vectors for functional assessment of oncogenes. Her prior business experience includes work in marketing for several European companies such as Kantor Management Consultants, ICAP Hellas, BSB Advertising, and K&D Direct Advertising.
|
Io holds an M.S. in Biotechnology Business from the University of Maryland and a B.S. in Business Administration/Marketing Management from The American College of Greece.
|
|
|
|
|
|
|
